Joshipura A, Salmataj S. A. Idiopathic Pulmonary Fibrosis: A Review on Molecular and Cellular Mechanisms. Biomed Pharmacol J 2022;15(1).

---

Manuscript received on :12-11-2020
Manuscript accepted on :08-09-2021
Published online on: 12-03-2022

---

Plagiarism Check: Yes
Reviewed by: Dr. Wang, Qixin
Second Review by: Dr. Francisco Solano Muñoz
Final Approval by: Dr. Omar M. E. Abdel-Salam

---

How to Citeclose    |   Publication History close

 Views: (Visited 685 times, 1 visits today)    PDF Downloads: 301

Akshat Joshipura and Salmataj S A*

Department of Biotechnology, Manipal Institute of Technology, MAHE, Manipal

Corresponding Author E-mail:Asalmataj.biotech@gmail.com

DOI : https://dx.doi.org/10.13005/bpj/2366

Abstract

Idiopathic pulmonary fibrosis is a progressive disease characterized by extracellular matrix accumulation and altered mechanical properties of lung tissue. Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is attracting considerable attention due to disease acceleration and substantial mortality. The biomechanical properties of tissues are sensed and responded to by mechanotransduction pathways that facilitate sensing of changes in mechanical cues by tissue resident cells and convert the mechanical signals into downstream biochemical signals. In this review pathways such as Wnt/β-catenin pathway, TGF-β/Smad signaling pathway and EMT in IPF, VEGF and its relation with PI3K–Akt signalling pathway, PI3-Akt pathway, PDGF Signalling Pathway, Hippo/YAP signalling, JAK/STAT pathway, Rnd3/p190/Rho-Gap pathway have been discussed. This review also covers current therapeutic strategies in relation to idiopathic pulmonary fibrosis.

Keywords

Idiopathic Pulmonary Fibrosis; IPF; Lung Tissue; Signalling

Introduction

Idiopathic pulmonary fibrosis is a progressive, chronic lung disorder, typically known to be fatal. With an unknown etiology and a medians survival of 3-4 years, it is one of the most aggressive members and the final pathway of the group of lung disorders known as interstitial lung disorders (ILD0 (Pardo et al., 2002). Also termed cryptogenic fibrosing alveolitis, it starts off as injuries to the lung epithelia and progresses towards chronic alveolar inflammation and finally leads to fibrosis (Wu et al., 2018). Chronic cough and dyspnoea are some of the more common symptoms, impairing the quality of life of the patient. Thoracic CT scans of patients with this disorder are known to show honeycombing zones (Well defined walls on subpleural cystic airspaces) (Martinez et al., 2017) fibroblastic foci, usual interstitial pneumonia (UIP), and patches (Sauleda et al., 2017) The main causes of lung injury that set off the whole cascade of inflammation and damage can be due to continual exposure to toxins like asbestos, silica, cigarette smoke, etc, or even elevated levels of oxygen, leading to ROS mediated damage.

Epidemiology and Occurrence

Having familial and sporadic variants, it is known to affect people worldwide, having no increased predisposition to any particular ethnicity or race. Despite being a rare disease, (<5 per 10000 person-years), in Europe alone, 40,000 new cases are diagnosed annually. IPF accounts for 20-50% of all ILD cases. Men are more prone to develop this disease and the progression occurs much faster too.

Pathways

Wnt/β-catenin pathway

This pathway is known to determine the fate of epithelial cells during their development. The Wnt family is the constituent of a group of growth factors that are highly conserved (Königshoff et al., 2008). These factors are glycoproteins rich in cysteine and are a vital part of organ development. Absence or defects of these lead to developmental abnormalities in embryonic stages and organ failure in later stages. Of the three different variants of the pathway, the β-catenin dependent Wnt pathway is considered to be canonical (Kim et al., 2008).

The canonical pathway starts with the inhibition of GSK-3β due to phosphorylation by Wnt proteins. This inhibition prevents the ubiquitylation and hence degradation of β-catenin. This causes cytoplasmic accumulation of β-catenin followed by nuclear translocation. In the nucleus, it binds with the lymphoid enhancer-binding factor (LEF) (synonymously-TCF i.e cell-specific transcription factor), consequently leading to transcription and regulation of the target genes of the signaling pathway such as TGF-β, matrix metallo-proteinases (MMPs)- 2,7 and 9 (Brabletz et al., 1999: Pardo et al., 2016) .

It has been reported that abnormal activation of the pathway occurs in IPF patients, leading to the progression of the disease. Elevated levels of nuclear-translocated β-catenin were found in them, especially in honeycomb modified bronchioles which are considered as abnormal lung architecture (Chilosi et al., 2003).

TGF-β/Smad signaling pathway and EMT in IPF

The pathogenesis of IPF through TGF-β signaling is closely related to the activity of myofibroblasts and this pathway is known as the “master switch” (Chen et al., 2016). These are fibroblasts that have differentiated on stimulation by an inflammatory response and usually express an intracellular contractile protein called alpha-smooth muscle actin (α-SMA). Therefore they are not present in normal lung tissue and are responsible for the repair, restoration of tissue, especially the extracellular matrix and scar formation (Hinz et al., 2016).

They are influenced by and secrete profibrotic growth factors called TGFβ (Transforming growth factor). TGFβ1 is an isoform of the multifunctional family of cytokines, primarily associated with IPF (Gharaee-Kermani et al., 2009). It stimulates differentiation of fibroblasts to myofibroblasts, which causes deposition of ECM proteins like fibrillin, fibronectin, and collagen at the site of injury and causes Epithelial to Mesenchymal transition (EMT) in alveolar type II epithelial cells (AECs) (marmai et al., 2011). These mesenchymal stem cells cause proliferation and hence with the combined effect of collagen deposition, accelerate the fibrotic process.

TGF- β1 levels, Smad 2/3, and α-SMA levels were found to be increased in rats with Bleomycin-induced EMT (Chen et al., 2016). TGF-β1 signaling starts when it binds to its serine/threonine kinase transmembrane receptor TGFβRII which phosphorylates serine/threonine residues in the transmembrane domain of the TGFβRI receptor. This activates the TGFβRI kinase that causes phosphorylative activation of Smad-2 and Smad-3, which later downstream, get attached to Smad-4, forming a heterotrimeric complex. This complex gets translocated to the nucleus where it interacts with transcription binding factors and regulates target genes that cause EMT (Gu et al., 2007).

Moreover, TGF-β further promotes fibrosis by signaling cells to produce profibrotic inflammatory molecules like PDGF, ILs (1B and 13), etc. and inhibits collagen and ECM degrading proteins called Matrix metalloproteases (MMPs) (Gyetko et al.,2009).

VEGF and its relation with PI3K–Akt signalling pathway

Vascular endothelial growth factor (VEGF), is a glycoprotein that promotes angiogenesis and hence vascularity. In the lungs, it is present in the alveolar epithelium (AEC) Normally, VEGF binds to tyrosine kinase receptors VEGFR1 and VEGFR2 which, by signal transduction, activate the P13K-AKT pathway as well as the FAK (Focal adhesion kinase) pathway. These pathways promote fibrosis by recruiting pro-fibrotic factors like TGFβ.

VEGF also has a direct contribution to fibrosis by association with angiogenic inflammatory chemokines like Monocyte Attractant protein (MCP-1) and IL-8 and hence promoting excessive ECM synthesis (Hosseinzadeh et al., 2018). Persons with IPF have been reported to have reduced levels of VEGF in the Bronchoalveolar lavage fluid but increased levels in the plasma.. VEGF increase in the plasma has been associated with poor gas exchange and a higher difference in alveolar- arterial oxygen. (AaDO2) (Hambly et al., 2015).

The PI3-Akt pathway

TGFB plays an important role here, in the activation of this pathway by stimulating autocrine secretions of growth factors, that in turn activate the PI3-Akt pathway. This pathway is an anti-apoptotic/pro-survival pathway. Phosphoinositide kinase 3 (PI3), at the membrane receptor gets activated by cytokines or growth factors like VEGF, and in turn activates Phosphatidylinositol triphosphate (PIP3), which, further downstream, activates Akt. This molecule is associated with inhibition of pro-Apoptotic signaling molecules and constituents like Caspase-9, Bax, and FOXO genes. It directly activates Bcl-XL and stimulates Mdm2, which is a negative regulator of p53.

Phosphatase and tensin homolog (PTEN) is an inhibitor of PIP3 and hence prevents stimulation of the multi-target pro-survival protein Akt. In IPF individuals, PTEN levels were found to be low, and hence a strong anti- apoptotic response is seen. Moreover, it was found that the Akt suppressed the powerful cell cycle inhibiting gene FOXO3a in the nucleus (Yan et al., 2014). Therefore, lower levels of PTEN and FOXO3a deficiency protects the fibroblasts from Apoptosis

PDGF Signalling Pathway

The mitogen PDGF is produced by lung epithelium during injuries, usually chronic. This includes smoke from tobacco/nicotine, tar, or work hazards like coal dust or asbestos. PDGF produced by this damaged epithelium may, by paracrine stimulation, cause unrestrained connective tissue fibroblast proliferation and collagen deposition (Antoniades et al., 1992). Alveolar macrophages are known to secrete PDGF-B, which is completely absent in healthy lung tissue. They also secrete PDGF-A. These chemoattractive factors bring more lung myofibroblasts, which secrete  PDGF-AA, which results in the formation and deposition of more collagen, contributing to the fibrosis (Bonner et al., 2010).

Hippo/YAP signalling

This pathway is known for its role in organ size regulation and apoptosis. This is carried out by gene products regulated by the transcriptional activator YAP (yes association protein). The presence of YAP leads to transcription, which then leads to the growth of the organ. The physiological importance of this was seen in studies on knockout mice (Brooks et al., 2007: Zheng et al., 2019) where overexpression of YAP led to a drastic increase in liver size, finally causing hepatocellular carcinoma.

YAP is suppressed by a kinase cascade, consisting of conserved protein kinases Mst1, Mst2 (mammalian Ste20-like kinases, which are Hippo homologs in mammals), Salvador (Sav1), Lats1, Lats2 (Large tumor suppressor, homologs of Wts), and Mob1 (Mats homologs) (Zheng et al., 2019) Mst-Sav1 complexes phosphorylate and activate the Lats, which further downstream cause phosphorylative inactivation of YAP.

In IPF individuals, nuclear YAP was found to be high (can also be verified by checking levels of Ajuba, the transcriptional target of YAP), while Sav and Mst1/2 are found to be suppressed. This can be compared with normal alveolar and bronchial cells where Sav and Mst1/2 are found in abundance (Gokey et al., 2018).

The JAK/STAT pathway

Janus kinase (JAK) is a family of tyrosine kinases with four members- JAK1, JAK2, JAK3, and Tyk2. Downstream effects of activation of JAK is proliferation, differentiation, and migration of cells (Rawlings et al.,2004). JAK gets activated and autophosphorylated on cytokine/growth factor binding (Valentino et al., 2006). These stimulants include VEGF, TGF-β, Angiotensins, and IL-6, 13.  JAK further activates the Signal transducer and activator of transcription (STAT) proteins by phosphorylation. This causes dimerization and nuclear translocation where target genes are transcribed.

As found frequently in IPF patients, JAK2 phosphorylation by TGF-β and other growth factors caused STAT3 activation and was found to promote fibrosis by conversion of fibroblasts to myofibroblasts. STAT3 activation by IL-6 is associated with Epithelial to Mesenchymal transition (EMT) (Milara et al., 2018).

Rnd3/p190/Rho-Gap pathway

RhoA is a GTPase that regulates cell motility and contractility using the actin-myosin bundle regulation and cytoskeleton (Monaghan-Benson et al., 2018). It is activated by either mechanical signals or the growth factor TGF–β. Inhibition of ROCK (Rho-associated coiled-coil containing protein kinase), a downstream protein regulated by RhoA, was found to decrease fibrosis.

Rho activity is enhanced in fibroblast, as compared to the normal level in healthy lung tissue and along with ROCK, is known to cause acute inflammation and fibrotic progression. This was confirmed by studies on RhoA miRNA silenced mice in which the collagen and fibronectin was reduced (Zhou et al., 2018).

Rnd3 is antagonistic to RhoA activity by activation of fp190RhoGAP (p190). Levels of Rnd3 were found to be low in IPF individuals and studies on the Rnd3 gene silenced with small-interfering RNA (siRNA) caused an increase in fibronectin, collagen, and SMA, hence confirming that loss on Rnd3 promotes fibrosis.

Immune system in IPF

The immune system is constantly active due to chronic injury and inflammation and can have the dual role of protection or promotion of fibrosis. However, in IPF, it was found that the contribution of the immune system to the progression of fibrosis outweighed the protective functions.

Innate immunity

The innate immunity mainly involves the alveolar macrophages, its Toll-like receptors (TLRs), and defensins (from neutrophils). TLR3, specifically, was found to be responsible for downregulating fibrotic proliferation. Studies on TLR3 genes with an SNP showed reduced cytokine production and hence an increase in fibrotic activity. TLR3 null mice had increased collagen deposition and profibrotic cytokine secretion (Ley et al., 2014).

Levels of other cytokines like IL-8, MCP-1/CCL2, and macrophage inflammatory protein MIP-1α were found to be higher in the lungs of IPF individuals. These cause chemotaxis and activation of monocytes, neutrophils and lymphocytes (Bringardner et al., 2008)

Adaptive immunity

These neutrophils are found to be key components in alveolitis due to the release of the proteolytic enzyme neutrophil elastase (NE). Heat shock protein (HSP70) was found to cause CD4 T cell activation, which produces profibrotic cytokines like IL-4. CD 28 null cells were found to be elevated in IPF patients and contributed to fibrosis. Th1 cells play a protective role by secreting IL-12, which induces pro-inflammatory cytokine IFNγ (Jakubsick et al., 2004). IFNγ is known to reduce mRNA levels of TGF-B, procollagen 1, and 2. Studies show that the levels of IFNγ reduce in the BALF and circulation of IPF patients (Desai et al., 2018). In contrast, Th2 derived cytokines like IL13, IL4, etc. excessively stimulate proliferation of alveolar macrophages that secrete CCL18/ PARC that stimulate collagen secretion and fibroblast-myofibroblast differentiation (Prasse et al., 2007). Th-17 cells are known to secrete IL-17, which was found to induce fibrotic lesions and collage accumulation in murine models. They also secrete IL-22, which in contrast to IL-17, has a protective role. However, the levels of Th-17 did not significantly differ in IPF and control and hence have to be studied further. Similarly, Innate Lymphoid Cells like NK cells have been identified in IPF, but their contributions remain unknown, as is the case with B cells (Desai e al., 2018).

Table 1: Current therapies

Conclusion

The pathogenesis of IPF through TGF-β signaling is closely related to the activity of myofibroblasts and this pathway. This review covers other transcription factors and pathways. Current therapeutic options slow the progression of IPF, but do not halt or reverse the scarring in the lung. The matrix is bioactive and plays a role the progression of IPF as a regulator of cellular phenotype and behavior. Mechanical cues that are first sensed via receptors on the cell membrane are converted to chemical signals via mechanotransduction pathways that regulate many aspects of cell behavior including motility, proliferation, morphology, and survival. Opportunities in targeting pathways to treat IPF have the potential, when combined with other therapeutic interventions, to halt the progression of fibrosis.

Acknowledgement

Authors are grateful to MAHE for the support.

Conflict of interest

there is no Conflict of interest.

Funding Sources

There is no funding sources.

References

1. Pardo, Annie, and Moisés Selman. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int. J. Biochem. 34: 1534-1538 (2002).
   CrossRef
2. Wu, Jin-Zhun, Dan-Dan Ge, Lin-Fu Zhou, Ling-Yun Hou, Ying Zhou, and Qi-Yuan Li. Effects of particulate matter on allergic respiratory diseases. Chronic Dis Transl Med 4, no. 2: 95-102 (2018).
   CrossRef
3. Martinez, Fernando J., Alison Chisholm, Harold R. Collard, Kevin R. Flaherty, Jeffrey Myers, Ganesh Raghu, Simon LF Walsh, Eric S. White, and Luca Richeldi. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. LancetRespir Med 5: 61-71 (2017).
   CrossRef
4. Sauleda, Jaume, Belén Núñez, Ernest Sala, and Joan B. Soriano. Idiopathic pulmonary fibrosis: epidemiology, natural history, phenotypes. Sci.  6: 110 (2018).
   CrossRef
5. Königshoff, Melanie, Nisha Balsara, Eva-Maria Pfaff, Monika Kramer, Izabella Chrobak, Werner Seeger, and Oliver Eickelberg. Functional Wnt signaling is increased in idiopathic pulmonary fibrosis. PloS one3: e2142  (2008).
   CrossRef
6. Kim, Kyung-Ah, Marie Wagle, Karolyn Tran, Xiaoming Zhan, Melissa A. Dixon, Shouchun Liu, Delphine Gros et al. R-Spondin family members regulate the Wnt pathway by a common mechanism.  Biol. Cell. 19: 2588-2596 (2008).
   CrossRef
7. Brabletz, Thomas, Andreas Jung, Serpil Dag, Falk Hlubek, and Thomas Kirchner. β-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer.  J. Pathol. 155: 1033-1038 (1999).
   CrossRef
8. Pardo, Annie, Sandra Cabrera, Mariel Maldonado, and Moisés Selman. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Res 17, 1: 23 (2016).
   CrossRef
9. Chilosi, Marco, Venerino Poletti, Alberto Zamò, Maurizio Lestani, Licia Montagna, Paola Piccoli, Serena Pedron et al. Aberrant Wnt/β-catenin pathway activation in idiopathic pulmonary fibrosis.  Am J Pathol 162: 1495-1502 (2003).
   CrossRef
10. Chen, Huaping, Jing Qu, Xiangwei Huang, Ashish Kurundkar, Lanyan Zhu, Naiheng Yang, Aida Venado et al. Mechanosensing by the α 6-integrin confers an invasive fibroblast phenotype and mediates lung fibrosis. Commun 7: 1-12 (2016).
    CrossRef
11. Hinz, Boris. Myofibroblasts. Exp. Eye Res 142: 56-70 (2016).
    CrossRef
12. Gharaee-Kermani, M., B. Hu, S. H. Phan, and M. R. Gyetko. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFβ signaling and the myofibroblast.  Med. Chem. 16,11: 1400-1417 (2009).
    CrossRef
13. Marmai, Cecilia, Rachel E. Sutherland, Kevin K. Kim, Gregory M. Dolganov, Xiaohui Fang, Sophia S. Kim, Shuwei Jiang et al. Alveolar epithelial cells express mesenchymal proteins in patients with idiopathic pulmonary fibrosis. AMJ PHYSIOL-LUNG C 301: L71-L78 (2011).
    CrossRef
14. Chen, Xiang, Chaowen Shi, Xiannan Meng, Kaijia Zhang, Xiaoyao Li, Cong Wang, Zou Xiang, Kebin Hu, and Xiaodong Han. Inhibition of Wnt/β-catenin signaling suppresses bleomycin-induced pulmonary fibrosis by attenuating the expression of TGF-β1 and FGF-2. Exp. Pathol 101: 22-30 (2016).
    CrossRef
15. Gu, Xuesong, Luiz F. Zerbini, Hasan H. Otu, Manoj Bhasin, Quanli Yang, Marie G. Joseph, Franck Grall, Tomi Onatunde, Ricardo G. Correa, and Towia A. Libermann. Reduced PDEF expression increases invasion and expression of mesenchymal genes in prostate cancer cells. Cancer Res 67: 4219-4226 (2007).
    CrossRef
16. Gyetko, M. R., & Gharaee-Kermani, M. In  IMMUNE MECHANISMS IN THE AIRWAY AND RESPONSE TO INJURY AND INFECTION(p. A3728). American Thoracic Society. (2009).
17. Hosseinzadeh, Azam, Seyed Ali Javad-Moosavi, Russel J. Reiter, Rasoul Yarahmadi, Habib Ghaznavi, and Saeed Mehrzadi. Oxidative/nitrosative stress, autophagy and apoptosis as therapeutic targets of melatonin in idiopathic pulmonary fibrosis. Expert Ther. Targets 22: 1049-1061 (2018).
    CrossRef
18. Hambly, Nathan, Chiko Shimbori, and Martin Kolb. Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers. Respirology 20, 7: 1010-1022 (2015).
    CrossRef
19. Yan, Zheng, and Zhu Ping. Reviews and prospectives of signaling pathway analysis in idiopathic pulmonary fibrosis.  Rev. 13: 1020-1025 (2014).
    CrossRef
20. Antoniades, Harry N., Janine Neville-Golden, Theofanis Galanopoulos, Richard L. Kradin, Anthony J. Valente, and Dana T. Graves. Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci 89: 5371-5375 (1992).
    CrossRef
21. Bonner, James C. Mesenchymal cell survival in airway and interstitial pulmonary fibrosis. Fibrogenesis Tissue Repair. 3: 15 (2010).
    CrossRef
22. Brooks, Craig, Qingqing Wei, Leping Feng, Guie Dong, Yanmei Tao, Lin Mei, Zi-Jian Xie, and Zheng Dong. Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins. Proc Natl Acad Sci 104: 11649-11654 (2007).
    CrossRef
23. Zheng, Yonggang, and Duojia Pan. The Hippo signaling pathway in development and disease.  Cell50: 264-282 (2019).
    CrossRef
24. Gokey, Jason J., Anusha Sridharan, Yan Xu, Jenna Green, Gianni Carraro, Barry R. Stripp, Anne-Karina T. Perl, and Jeffrey A. Whitsett. Active epithelial Hippo signaling in idiopathic pulmonary fibrosis. JCI insight3 :(2018).
    CrossRef
25. Rawlings, Jason S., Kristin M. Rosler, and Douglas A. Harrison. The JAK/STAT signaling pathway. Cell Sci. 117: 1281-1283 (2004).
    CrossRef
26. Valentino, Lyne, and Josiane Pierre. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Pharmacol. 71: 713-721 (2006)
    CrossRef
27. Milara, Javier, Gracia Hernandez, Beatriz Ballester, Anselm Morell, Inés Roger, P. Montero, Juan Escrivá et al. “The JAK2 pathway is activated in idiopathic pulmonary fibrosis.” Respir Res19: 24 (2018).
    CrossRef
28. Monaghan-Benson, Elizabeth, Erika S. Wittchen, Claire M. Doerschuk, and Keith Burridge. A Rnd3/p190RhoGAP pathway regulates RhoA activity in idiopathic pulmonary fibrosis fibroblasts. Biol. Cell 29: 2165-2175 (2018).
    CrossRef
29. Zhou, Yong, Xiangwei Huang, Louise Hecker, Deepali Kurundkar, Ashish Kurundkar, Hui Liu, Tong-Huan Jin, Leena Desai, Karen Bernard, and Victor J. Thannickal. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. Clin. Investig. 123: 1096-1108 (2013).
    CrossRef
30. Ley, Brett, Kevin K. Brown, and Harold R. Collard. Molecular biomarkers in idiopathic pulmonary fibrosis. AMJ PHYSIOL-LUNG C 307: L681-L691 (2014).
    CrossRef
31. Bringardner, Benjamin D., Christopher P. Baran, Timothy D. Eubank, and Clay B. Marsh. The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Redox Signal. 10: 287-302 (2008).
    CrossRef
32. Jakubzick, Claudia, Steven L. Kunkel, Raj K. Puri, and Cory M. Hogaboam. Therapeutic targeting of IL-4-and IL-13-responsive cells in pulmonary fibrosis.  Res 30: 339-349 (2004).
    CrossRef
33. Desai, Pinkal, Nuria Mencia-Trinchant, Oleksandr Savenkov, Michael S. Simon, Gloria Cheang, Sangmin Lee, Michael Samuel et al. Somatic mutations precede acute myeloid leukemia years before diagnosis. Med 24: 1015-1023 (2018).
    CrossRef
34. Prasse, Antje, Dmitri V. Pechkovsky, Galen B. Toews, Markus Schäfer, Stephan Eggeling, Corinna Ludwig, Martin Germann, Florian Kollert, Gernot Zissel, and Joachim Müller‐Quernheim. “CCL18 as an indicator of pulmonary fibrotic activity in idiopathic interstitial pneumonias and systemic sclerosis.” ArthritisRheum 56, no. 5 (2007): 1685-1693.
    CrossRef
35. CHITRA, SANKARAN. Interrogating Gender in a Singapore Classroom. Routledge, 2015.
36. Murray, Claire E., Robert R. Lindner, Snežana Stanimirović, W. M. Goss, Carl Heiles, John Dickey, Nickolas M. Pingel et al. Excitation Temperature of the Warm Neutral Medium as a New Probe of the Lyα Radiation Field. J. Lett. 781: L41 (2014).
    CrossRef
37. Clarke, Deborah L., Lynne A. Murray, Bruno Crestani, and Matthew A. Sleeman. Is personalised medicine the key to heterogeneity in idiopathic pulmonary fibrosis? Ther 169: 35-46 (2017).
    CrossRef
38. Rafii, Rokhsara, Maya M. Juarez, Timothy E. Albertson, and Andrew L. Chan. A review of current and novel therapies for idiopathic pulmonary fibrosis. J Thorac Dis5: 48 (2013).